

## Precigen Selects McKesson to Support Specialty Pharmacy and Patient Hub Services for Launch of Novel Immunotherapy

**IRVING, Texas, September 25, 2025** — [InspiroGene™ by McKesson](#), a dedicated business focused on supporting the commercialization of cell and gene therapies (CGTs), today announced that it has been selected by [Precigen](#) (Nasdaq: PGEN) to support the launch of PAPZIMEOS™ (zopapogene imadenovec-drba), Precigen's novel immunotherapy approved by the U.S. Food and Drug Administration on August 14, 2025.

As a part of this collaboration, Precigen has selected [Biologics by McKesson](#) as their exclusive provider of specialty pharmacy and patient hub services. By combining Biologics by McKesson's 30+ years in specialty pharmacy expertise with the InspiroCare CGT patient hub, InspiroGene is driving broader access and a more connected experience for all stakeholders.

"Our commitment at Precigen is not only to bring therapies like PAPZIMEOS to patients, but also to ensure that access to these therapies is seamless," said Phil Tennant, Chief Commercial Officer of Precigen. "McKesson allows us to match scientific innovation with operational excellence, creating a connected ecosystem that supports patients, providers, and caregivers alike. Their proven expertise in specialty pharmacy and patient hub services will support our efforts to ensure that all eligible patients have access to therapy."

"InspiroGene is honored to be Precigen's exclusive provider for specialty pharmacy and patient hub services for PAPZIMEOS," said Joe DePinto, Head of Cell, Gene, and Advanced Therapies at McKesson. "Through our InspiroCare patient services hub, we are setting a new standard for support in cell, gene, and advanced therapies, ensuring that patients receiving PAPZIMEOS have seamless access to support services."

The recently-launched [InspiroCare](#) is the first-of-its kind patient hub, exclusively designed for cell, gene, and advanced therapies. InspiroCare provides patients, caregivers, and healthcare providers with comprehensive support and vital information throughout the treatment journey, ensuring a cohesive and empowering experience.

### About InspiroGene by McKesson

InspiroGene by McKesson ("InspiroGene") is a dedicated business unit focused solely on supporting the commercialization of cell and gene therapies (CGTs). At InspiroGene, we turn CGT innovation into a reality. We offer flexible, sustainable solutions to help manufacturers, payers, and providers navigate the complex CGT commercialization landscape. As an enduring ally, we're dedicated to transforming patient care and driving better health outcomes. Learn more about the InspiroGene advantage at [InspiroGene.com](#).

### **About McKesson Corporation**

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at [McKesson.com](https://mckesson.com) and read [Our Stories](#).

### **PR Contact**

InspiroGene by McKesson  
Lindsay Yanek, Communications  
[Lindsay.Yanek@McKesson.com](mailto:Lindsay.Yanek@McKesson.com)